C4 Therapeutics, Inc. (CCCC)

Market Cap	124.23M
Revenue (ttm)	35.58M
Net Income (ttm)	-105.32M
Shares Out	70.99M
EPS (ttm)	-1.52
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	474,286
Open	1.830
Previous Close	1.840
Day's Range	1.740 - 1.825
52-Week Range	1.740 - 8.290
Beta	3.00
Analysts	Buy
Price Target	12.50 (+614.29%)
Earnings Date	May 7, 2025

About CCCC

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is Cemsidomide, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developin...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 2, 2020
• Employees: 110
• Stock Exchange: NASDAQ
• Ticker Symbol: CCCC
• Website: https://www.c4therapeutics.com

Financial Performance

In 2024, C4 Therapeutics's revenue was $35.58 million, an increase of 71.44% compared to the previous year's $20.76 million. Losses were -$105.32 million, -20.51% less than in 2023.

Analyst Forecast

According to 4 analysts, the average rating for CCCC stock is "Buy." The 12-month stock price forecast is $12.5, which is an increase of 614.29% from the latest price.

Price Target

$12.5

(614.29% upside)

Analyst Consensus: Buy